Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Notes Payables (2019 - 2026)

Biodesix filings provide 8 years of Notes Payables readings, the most recent being $2000.0 for Q1 2026.

  • On a quarterly basis, Notes Payables fell 88.89% to $2000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $2000.0, a 88.89% decrease, with the full-year FY2025 number at $6000.0, down 71.43% from a year prior.
  • Notes Payables hit $2000.0 in Q1 2026 for Biodesix, down from $6000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $14.3 million in Q3 2022 to a low of $2000.0 in Q1 2026.
  • Median Notes Payables over the past 5 years was $45000.0 (2024), compared with a mean of $1.6 million.
  • Biggest five-year swings in Notes Payables: surged 71570.0% in 2022 and later plummeted 99.65% in 2023.
  • Biodesix's Notes Payables stood at $49000.0 in 2022, then grew by 4.08% to $51000.0 in 2023, then crashed by 58.82% to $21000.0 in 2024, then tumbled by 71.43% to $6000.0 in 2025, then crashed by 66.67% to $2000.0 in 2026.
  • The last three reported values for Notes Payables were $2000.0 (Q1 2026), $6000.0 (Q4 2025), and $11000.0 (Q3 2025) per Business Quant data.